Steri-Oss to distribute tissue monitor in North America:
This article was originally published in Clinica
Steri-Oss is to have exclusive rights to distribute Xytronyx's periodontal tissue monitor in North America and certain other countries for five years. The product, under US FDA review, is marketed by Hawe-Neos Dental in Europe and will be distributed by Shofu in Japan once approval has been received. Both Xytronyx and Steri-Oss are based in California.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.